List of Excipients in Branded Drug CIMETIDINE HYDROCHLORIDE ORAL SOLUTION

« Back to Dashboard

Generic Drugs Containing CIMETIDINE HYDROCHLORIDE ORAL SOLUTION

Company	Ingredient	NDC	Excipient
Akorn Operating Company LLC	cimetidine hydrochloride oral solution	50383-050	FD&C YELLOW NO. 6
Akorn Operating Company LLC	cimetidine hydrochloride oral solution	50383-050	HYDROCHLORIC ACID
Akorn Operating Company LLC	cimetidine hydrochloride oral solution	50383-050	METHYLPARABEN
Akorn Operating Company LLC	cimetidine hydrochloride oral solution	50383-050	ORANGE
Akorn Operating Company LLC	cimetidine hydrochloride oral solution	50383-050	POLOXAMER 188
Akorn Operating Company LLC	cimetidine hydrochloride oral solution	50383-050	PROPYLENE GLYCOL

What are the Most Frequently-Used Excipients in CIMETIDINE HYDROCHLORIDE ORAL SOLUTION?

# Of NDCs	Excipient
1	FD&C YELLOW NO. 6
1	HYDROCHLORIC ACID
1	METHYLPARABEN
1	ORANGE
1	POLOXAMER 188
1	PROPYLENE GLYCOL

Cimetidine Hydrochloride Oral Solution: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 4, 2026

Cimetidine hydrochloride oral solution is a mature, low-barrier generic product with limited active-ingredient patent protection and meaningful formulation opportunities. The strongest commercial positions are likely to come from pediatric and dysphagia-friendly dosing, sugar-free and alcohol-free excipient systems, preservative-free unit-dose packaging, feeding-tube compatibility, and supply reliability rather than from exclusivity over cimetidine itself.

What is the commercial status of cimetidine hydrochloride oral solution?

Cimetidine is an H2-receptor antagonist approved for acid-related gastrointestinal conditions, including duodenal ulcer, gastric ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. The drug was commercialized by SmithKline Beecham under Tagamet and has been available as a generic for decades.

The active ingredient has no meaningful remaining U.S. composition-of-matter exclusivity. Commercial protection would therefore depend on:

• Product quality and supply reliability
• Differentiated excipient selection
• Pediatric or institutional positioning
• Packaging and dosing-device design
• Formulation patents, if technically defensible
• Regulatory exclusivity tied to a genuinely new indication or population

Cimetidine is less commercially attractive than famotidine for many adult indications because of its extensive cytochrome P450 enzyme inhibition and clinically important drug-interaction profile. Famotidine and proton-pump inhibitors constrain broad substitution opportunities, but cimetidine remains relevant where low acquisition cost, established clinical experience, or liquid administration is required.

Likely target product profile

Attribute	Commercially relevant target
Active ingredient	Cimetidine hydrochloride, labeled by cimetidine equivalent
Common concentration	300 mg/5 mL, equivalent to 60 mg/mL cimetidine
Dosage form	Ready-to-use oral solution
Administration	Oral syringe, cup, or enteral feeding tube
Sugar	Preferably sucrose-free
Alcohol	Preferably alcohol-free
Preservative	Multidose system may require preservation; unit-dose format can be preservative-free
pH	Acidic to mildly acidic, selected for solubility and stability
Packaging	Amber bottle, unit-dose cup, or oral-syringe presentation
Regulatory route	Abbreviated New Drug Application for a pharmaceutically equivalent generic product
Primary users	Pediatric patients, dysphagia patients, long-term-care residents, hospitals, and patients using feeding tubes

What excipients are appropriate for cimetidine hydrochloride oral solution?

The excipient system should prioritize salt solubility, pH control, palatability, microbial protection, chemical stability, and compatibility with dosing devices. The formulation must be developed around the labeled cimetidine-equivalent concentration rather than the gross mass of cimetidine hydrochloride salt.

Recommended excipient architecture

Formulation function	Candidate excipients	Development rationale
Vehicle	Purified water	Standard aqueous vehicle with broad regulatory familiarity
pH control	Citric acid, sodium citrate, hydrochloric acid, sodium hydroxide	Maintains solubility and controls taste and preservative performance
Sweetener	Sorbitol, sucralose, sodium saccharin, acesulfame potassium	Supports sugar-free positioning
Bulking agent	Sorbitol or glycerin	Improves mouthfeel and supports dose uniformity
Viscosity modifier	Hydroxyethylcellulose, xanthan gum, or hypromellose	Helps suspend or control flow, but may complicate tube administration
Flavor	Fruit or berry flavor system	Masks bitterness and sulfur-related or medicinal notes
Preservative	Methylparaben, propylparaben, potassium sorbate, or sodium benzoate	Required only when justified by multidose microbiological risk
Chelating agent	Disodium edetate	May improve preservative performance and reduce metal-catalyzed degradation
Antioxidant	Product-specific; generally not a first-line requirement	Should be used only if oxidative degradation is demonstrated
Wetting or solubilizing agent	Usually unnecessary for a fully soluble salt	Avoids unnecessary surfactant exposure and taste burden

The preferred initial development path is a clear, aqueous, sugar-free solution using a citrate buffer, sorbitol or a high-intensity sweetener, flavor, purified water, and either a validated preservative system or unit-dose packaging.

Why pH is the central formulation variable

Cimetidine is a basic compound. The hydrochloride salt improves aqueous handling, but pH still affects solubility, taste, preservative efficacy, chemical stability, and gastrointestinal tolerability. A lower pH can improve ionization and solution clarity, while excessive acidity may increase sourness and reduce patient acceptance.

The development program should map:

1. Solubility across the intended pH range.
2. Assay and degradation products under accelerated and long-term conditions.
3. Flavor performance after storage.
4. Preservative effectiveness at the final pH.
5. Container-closure interaction.
6. Compatibility with oral syringes and enteral tubes.

A citrate-buffered system is commercially familiar, but citrate can produce a noticeable sour profile. A low-buffer-capacity system may improve taste while reducing pH drift during storage. The final choice should be determined by stability and palatability data rather than excipient familiarity alone.

Which excipient strategy creates the strongest commercial differentiation?

The strongest strategy is a platform with separate presentations for retail, pediatric, and institutional channels.

1. Sugar-free and alcohol-free solution

A sucrose-free product has a clear use case in pediatric patients, patients with diabetes, and long-term therapy. Sorbitol, sucralose, or sodium saccharin can replace sucrose, but sorbitol levels must be controlled because excessive exposure can cause gastrointestinal discomfort or laxative effects.

An alcohol-free formulation improves suitability for children, older adults, and chronic-use patients. It also removes a point of differentiation used by some liquid medicines.

2. Preservative-free unit-dose product

A preservative-free oral solution in single-use cups or prefilled oral syringes can target:

• Neonatal and pediatric hospitals
• Long-term-care facilities
• Emergency departments
• Home-care patients with swallowing difficulty
• Institutions seeking reduced medication-preparation steps

The tradeoff is higher packaging cost and lower flexibility for large-volume dispensing. Unit-dose packaging is most defensible when the product reduces medication errors, contamination risk, or nursing time.

3. Feeding-tube compatible product

A low-viscosity, low-foaming solution with controlled osmolality can support enteral administration. The formulation should be tested through commonly used polyurethane and silicone tubes at relevant French-size dimensions.

Testing should assess:

• Delivered dose recovery
• Tube occlusion
• Adsorption to tubing
• Flush-volume requirements
• Compatibility with water flushes
• Compatibility with common enteral nutrition products
• Stability after dispensing into oral syringes

A feeding-tube claim requires evidence. It should not be inferred from the product being a solution.

4. Pediatric taste-masked product

Cimetidine can present bitterness and a medicinal taste. A fruit flavor alone may not sufficiently mask the active ingredient. Development options include:

• High-intensity sweetener combinations
• Flavor layering
• pH adjustment
• Increased viscosity for reduced oral spread
• Ion-exchange resin complexation
• Cyclodextrin complexation
• Microencapsulation

Complexation and encapsulation may create new regulatory and manufacturing burdens. They are more valuable if the product targets pediatric adherence and can demonstrate a measurable taste advantage over conventional liquids.

5. Low-osmolality formulation

Low osmolality can improve tolerability, particularly in pediatric and enteral use. Sorbitol, glycerin, and high concentrations of soluble salts can increase osmolality. The development target should balance palatability, solubility, and gastrointestinal tolerance.

What patents protect cimetidine hydrochloride oral solution?

The original cimetidine composition-of-matter and basic product patents are expired. Cimetidine was introduced in the late 1970s, and any original U.S. patent protection expired long ago after accounting for the patent term applicable at the time.

The relevant current intellectual-property categories are:

IP category	Expected relevance
Original cimetidine compound patents	Expired
Basic oral-solution claims	Likely weak or expired unless tied to a novel formulation
Specific excipient combinations	Potentially protectable if they solve a demonstrated stability, palatability, or preservation problem
Taste-masking technology	Potentially protectable, depending on mechanism and claim scope
Unit-dose packaging	Potentially protectable, but vulnerable to design-around
Feeding-tube administration	Potentially protectable only with a specific technical formulation or administration method
New indication	Potentially protectable under method-of-use claims
Manufacturing process	Potentially protectable if the process produces a defined purity or stability advantage
Trade dress and device configuration	May support commercial differentiation but usually provides limited patent strength

A new patent estate would be strongest if it claims a defined formulation range tied to objective performance, such as:

• A specific pH and buffer system that improves stability.
• A preservative system that passes antimicrobial effectiveness testing at a reduced preservative concentration.
• A taste-masked system with a defined release or sensory profile.
• A low-osmolality formulation that maintains concentration and stability.
• A formulation with demonstrated enteral-tube dose recovery.

Broad claims covering “cimetidine in an oral solution with a sweetener” would face substantial validity and obviousness risks because oral solutions, sweeteners, buffers, flavors, and preservatives are conventional pharmaceutical excipients.

What is the FDA regulatory status and Orange Book position?

Cimetidine is an FDA-approved active ingredient with generic-market history. A new cimetidine hydrochloride oral solution would generally be evaluated as a generic product if it matches a reference product in active ingredient, dosage form, strength, route, and relevant quality attributes.

The principal regulatory questions are:

• Whether a current reference-listed drug exists for the proposed dosage form and strength.
• Whether the proposed product is pharmaceutically equivalent to that reference.
• Whether the formulation contains permissible inactive ingredients at the proposed route and concentration.
• Whether the product requires a new drug application rather than an abbreviated application because of a meaningful formulation or indication difference.
• Whether the dosage form is listed in the Orange Book under the same active ingredient and route.

The Orange Book generally lists approved drug products and patent or exclusivity information associated with approved applications. Because cimetidine is an old small-molecule product, active patent listings are unlikely to provide a substantial barrier for a conventional oral solution. Orange Book status must be checked against the current FDA database before filing because product listings, discontinued products, and reference-product designations can change. [1]

Paragraph IV challenge risk

A conventional cimetidine oral solution with no listed patents would not face a meaningful Paragraph IV patent challenge. If a sponsor obtains later-issued formulation patents and lists them in the Orange Book, a competing applicant could challenge those patents through a Paragraph IV certification.

The commercial significance of a Paragraph IV strategy would depend on:

• Whether the patent claims are listed against the approved product.
• Whether the claims cover the entire commercial formulation or only a narrow variant.
• Whether the patent owner has demonstrated a meaningful formulation advantage.
• Whether the expected market is large enough to support litigation.

For a low-value mature generic, litigation economics are usually unfavorable unless the product has a protected institutional contract, shortage-driven demand, or a differentiated pediatric market.

When does cimetidine lose exclusivity?

Cimetidine lost its original market exclusivity decades ago. The current commercial issue is not loss of exclusivity but whether a sponsor can establish new, enforceable protection around a formulation or use.

Exclusivity type	Status for conventional cimetidine oral solution
Original active-ingredient patent	Expired
Original pioneer exclusivity	Expired
Standard generic competition	Permitted, subject to approval requirements
New formulation patent	Possible, but technically narrow
New pediatric study exclusivity	Possible only if qualifying new clinical studies support an approved change
Orphan-drug exclusivity	Not applicable to ordinary cimetidine indications
Biosimilar exclusivity	Not applicable

There is no biosimilar pathway for cimetidine because it is a chemically synthesized small molecule. Competition would come from generic drug applicants, authorized generics, compounding pharmacies, and potentially outsourcing facilities.

Which companies are likely to challenge or compete with cimetidine oral solution?

The competitive set includes generic manufacturers with liquid-dose capabilities, contract development and manufacturing organizations, compounding pharmacies, and suppliers of competing acid-suppression drugs.

Direct competitors

Potential direct competitors include manufacturers marketing or capable of marketing:

• Cimetidine oral solution
• Cimetidine syrup
• Cimetidine tablets that can be compounded or dispersed
• Hospital or pharmacy-compounded cimetidine liquids

The relevant company set may change because mature products are frequently discontinued, acquired, or supplied through private-label arrangements.

Therapeutic competitors

Product class	Examples	Competitive impact
H2 antagonists	Famotidine	Stronger interaction profile and often preferred clinically
Proton-pump inhibitors	Omeprazole, lansoprazole, pantoprazole	Greater acid suppression; liquid or suspension formulations may compete
Antacids	Aluminum hydroxide, magnesium hydroxide, calcium carbonate	Lower-cost episodic treatment
Alginate products	Alginate-antacid combinations	Compete in reflux symptom management
Compounded liquids	Pharmacy-prepared suspensions or solutions	Flexible dosing but variable availability and quality

Cimetidine's main competitive weakness is interaction burden. It inhibits several CYP enzymes, including CYP1A2, CYP2C9, CYP2D6, and CYP3A4 to clinically relevant degrees. The product label identifies interactions with drugs such as warfarin, phenytoin, theophylline, lidocaine, and certain benzodiazepines. [2] A commercial strategy should therefore target use cases where a liquid H2 antagonist is needed and interaction screening is manageable.

What manufacturing and excipient barriers affect commercialization?

The technical barriers are moderate, but the product must meet liquid-dose quality expectations.

Critical quality attributes

• Appearance and clarity
• Assay and content uniformity
• pH
• Related substances
• Microbial limits
• Preservative content, if applicable
• Preservative effectiveness
• Viscosity
• Osmolality
• Specific gravity
• Fill volume
• Container-closure integrity
• In-use stability
• Dose delivery through the proposed device

Manufacturing risks

A clear oral solution reduces manufacturing complexity compared with a suspension, but it introduces sensitivity to:

• pH drift
• Salt precipitation
• Flavor instability
• Preservative partitioning
• Adsorption to plastic packaging
• Extractables and leachables
• Microbial contamination after opening
• Dose loss in oral syringes
• Crystallization during temperature excursions

The preferred manufacturing process is typically aqueous compounding under controlled temperature, followed by filtration where compatible with the formulation and validated filling into an appropriate container-closure system. Sterile manufacturing is generally unnecessary for an ordinary oral solution, but microbiological controls remain essential.

Packaging options

Package	Best use	Limitation
Amber HDPE bottle	Retail multidose product	Requires preservative and in-use stability program
Amber glass bottle	Strong barrier and broad compatibility	Breakage and higher logistics cost
Unit-dose cup	Institutional distribution	Higher packaging cost
Prefilled oral syringe	Pediatric and dysphagia use	More complex filling and device validation
Sachet or stick pack	Portable dosing	Less suitable for repeated daily dosing

A child-resistant multidose bottle with an oral syringe is likely the lowest-cost commercial configuration. Unit-dose syringes offer stronger differentiation but require a higher-value channel.

What generic launch scenarios exist for cimetidine oral solution?

Scenario 1: Low-cost conventional generic

The sponsor launches a 300 mg/5 mL oral solution in a standard bottle. The product competes on price and availability.

• Lowest development cost
• Weak differentiation
• High exposure to contract pricing
• Limited patent value
• Suitable for a supplier with existing liquid manufacturing capacity

Scenario 2: Pediatric and dysphagia product

The sponsor launches a sugar-free, alcohol-free formulation with an oral syringe and child-appropriate flavor.

• Higher retail and specialty-pharmacy value
• Better adherence positioning
• Greater taste-testing burden
• More opportunity for formulation claims
• Requires careful preservative and osmolality strategy

Scenario 3: Institutional unit-dose product

The sponsor supplies preservative-free unit-dose cups or syringes to hospitals and long-term-care facilities.

• Potential reduction in medication-preparation burden
• Higher packaging and quality costs
• Potential contracting opportunity
• Less direct retail competition
• Demand may be limited by cimetidine's interaction profile

Scenario 4: Specialty formulation

The sponsor develops a low-osmolality, feeding-tube-compatible formulation with validated dose recovery.

• Strongest technical differentiation
• More extensive compatibility studies
• Potentially defensible formulation patent
• Market size remains narrow
• Commercial success depends on institutional adoption

How strong is the patent estate for cimetidine hydrochloride oral solution?

The patent estate is weak for an ordinary solution and potentially moderate for a technically differentiated product.

Product concept	Patent strength	Commercial attractiveness
Standard cimetidine solution with common sweetener	Low	Low to moderate
Sugar-free, alcohol-free solution	Low to moderate	Moderate
Preservative-free unit-dose solution	Moderate if linked to package and stability data	Moderate
Taste-masked pediatric solution	Moderate	Moderate to high in a niche
Feeding-tube optimized product	Moderate	Moderate
Novel cimetidine delivery system	Potentially higher	Uncertain because of development cost
New approved indication	Potentially high	Dependent on clinical evidence and market size

The most credible patent strategy is a narrow formulation patent supported by comparative data. Trade-secret protection for flavor composition, processing parameters, preservative optimization, and packaging controls may be more durable than broad patent claims.

What revenue exposure and licensing opportunities exist?

Cimetidine is unlikely to support blockbuster economics. Revenue potential is concentrated in underserved formats rather than in broad adult acid-suppression use.

Commercial opportunity ranking

1. Pediatric and dysphagia liquid dosing.
2. Reliable supply during shortages or manufacturer withdrawals.
3. Institutional unit-dose products.
4. Feeding-tube administration.
5. International markets with limited access to modern H2 antagonists.
6. Standard retail generic solution.

Licensing opportunities may arise through:

• Contract manufacturing of liquid formulations
• Private-label supply to hospital distributors
• Regional rights for pediatric products
• Licensing of taste-masking technology
• Packaging partnerships for prefilled oral syringes
• Supply agreements with long-term-care pharmacy networks

A licensing deal should focus on manufacturing know-how, device integration, or channel access. Licensing the cimetidine molecule itself would have limited value because the active ingredient is off-patent.

Key Takeaways

• Cimetidine hydrochloride oral solution has no meaningful original patent barrier.
• A conventional generic solution is commercially vulnerable to price competition.
• The strongest opportunities are pediatric dosing, dysphagia, feeding-tube use, and institutional unit-dose packaging.
• Sugar-free and alcohol-free positioning is commercially useful but unlikely to create strong patent protection by itself.
• Preservative-free packaging can support differentiation if the sponsor accepts higher packaging costs.
• Cimetidine's CYP-mediated drug interactions limit broad clinical substitution against famotidine and proton-pump inhibitors.
• A defensible patent strategy requires objective performance data tied to pH, stability, taste masking, osmolality, tube compatibility, or packaging.
• There is no biosimilar risk because cimetidine is a small-molecule drug.
• The preferred development path is a clear aqueous solution with controlled pH, low osmolality, acceptable taste, validated microbiological protection, and an oral-syringe presentation.

FAQs

Is cimetidine hydrochloride oral solution still commercially relevant?

Yes, but primarily in niche liquid-dose markets. Pediatric patients, patients with dysphagia, feeding-tube users, and institutional customers are more relevant targets than the broad adult acid-suppression market.

Can a sugar-free cimetidine solution receive patent protection?

Sugar-free status alone is unlikely to support a strong patent. Protection is more credible when the excipient system produces demonstrated stability, taste, osmolality, preservative, or dosing benefits.

Is cimetidine oral solution suitable for pediatric development?

It can be suitable where liquid administration is needed, but pediatric development must address taste, dosing accuracy, osmolality, excipient exposure, and cimetidine's drug-interaction profile.

Does cimetidine oral solution require a preservative?

A multidose bottle will generally require a validated antimicrobial strategy unless the package and use design sufficiently control microbial risk. A unit-dose, preservative-free presentation can avoid routine multidose preservation requirements.

Can cimetidine oral solution be administered through an enteral feeding tube?

A solution may be administrable through a feeding tube, but the commercial product should support the claim with tube-specific dose-recovery, occlusion, adsorption, and flush-compatibility data.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

2. DailyMed. (2024). Cimetidine hydrochloride oral solution prescribing information. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.

5. U.S. Food and Drug Administration. (2024). Q1A(R2) stability testing of new drug substances and products. FDA.

6. U.S. Food and Drug Administration. (2024). Q6A specifications: Test procedures and acceptance criteria for new drug substances and new drug products. FDA.